Discuss AOD-9604 + CJC-1295 + Ipamorelin on glp1chat
Join the forum to discuss research with other members.
At a glance
This record combines AOD-9604, studied for fat metabolism, with CJC-1295 and ipamorelin, which signal growth hormone release through different pathways. The proposed effects come from the individual components; their combined result has to be tested as its own preparation.
The three parts ask different questions: AOD-9604 concerns fat handling, while the CJC-1295 form and ipamorelin signal growth hormone release through different receptors. That gives researchers a reason to examine the combination, but does not tell them its net effect. The exact CJC-1295 form, proportions and delivery all matter. Results from the separate ingredients cannot substitute for a study of this complete preparation.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Most component findings must be interpreted separately from evidence for the complete preparation. A co-administration study does not automatically validate a premixed vial, and a blended total is not the dose of each constituent.[1][5][2]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of AOD-9604 + CJC-1295 + Ipamorelin.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 12 mg · 1 source tables
Standard / Gradual Approach (3 mL reconstitution)
| Week | Daily Dose | Units (mL) |
|---|---|---|
| Week 1 | 200 mcg AOD / 100 mcg CJC / 100 mcg Ip | 10 units (0.10 mL) |
| Week 2 | 300 mcg AOD / 150 mcg CJC / 150 mcg Ip | 15 units (0.15 mL) |
| Weeks 3–12 | 400 mcg AOD / 200 mcg CJC / 200 mcg Ip | 20 units (0.20 mL) |
Concentration after reconstitution: 2.0 mg/mL AOD-9604 | 1.0 mg/mL CJC-1295 | 1.0 mg/mL Ipamorelin Frequency: Inject once daily subcutaneously, preferably in the morning or before bed on an empty stomach. For ≤10‑unit (≤0.10 mL) administrations during titration, consider 30‑ or 50‑unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support body composition improvements through combined lipolytic and GH-stimulating mechanisms[4][5].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 200–400 mcg AOD / 100–200 mcg CJC / 100–200 mcg Ip daily with gradual titration.
- Reconstitution: 3.0 mL per 12 mg vial (4 mg/mL total concentration).
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 0.10 mL daily (200 mcg AOD / 100 mcg CJC / 100 mcg Ip); increase by ~0.05 mL weekly as tolerated.
- Target: 0.20 mL daily (400 mcg AOD / 200 mcg CJC / 200 mcg Ip) by Week 3.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Morning or before bed on an empty stomach; rotate injection sites.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 28 days per CDC/USP guidelines[6].
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[9].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[10][11].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[10].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[12].
- Dispose of used syringes in an approved sharps container; follow local disposal regulations.
Materials & quantity planning
Source materials checklist · 12 mg
Plan based on an 8–16 week daily protocol with gradual titration (maintenance dose: 0.20 mL/day).
- Peptide Blend Vials (12 mg each):
- 8 weeks (~11.2 mL total): 4 vials
- 12 weeks (~16.8 mL total): 6 vials
- 16 weeks (~22.4 mL total): 8 vials
- Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
- Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- 16 weeks (8 vials): 24 mL → 3 × 10 mL bottles
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 12 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
- 03
Research publication
European Journal of Endocrinology (PubMed) — Ipamorelin: the first selective growth hormone secretagogue (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
Translational Andrology and Urology (PMC) — Role of growth hormone secretagogues in body composition management (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 05
- 06
Public health resource
CDC — Preventing unsafe injection practices: multi-dose vial handling guidelines (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Research publication
Obesity Pharmacotherapy Review (PMC) — AOD-9604 clinical trial overview and weight loss outcomes (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site guidance) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 11
Public health resource
MedlinePlus — Subcutaneous injections: patient instructions and technique (opens in a new tab)medlineplus.gov
Back to overview ↑ - 12
Public health resource
NCBI Bookshelf — Best practices for injection: asepsis, preparation, and administration (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 13
Research publication
Central & Peripheral Anti-Obesity Targets (PMC) — AOD-9604 RCT summary and mechanistic overview (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 14
Research publication
PubMed — Metabolic studies of AOD-9604 in obese rodents (oral dosing, fat oxidation) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.